Meet
Kolton Gustafson

Kolton Gustafson assists clients in evaluating the impact of federal health policy developments on their business priorities and policy engagement strategies.

He uses his experience in government payment systems and reimbursement and his familiarity with provider perspectives to support engagements in drug pricing, physician payment, Medicare reimbursement, and healthcare reform.

Prior to joining Avalere, Kolton was a senior analyst at Partners HealthCare where he monitored Medicare and Medicaid policy changes to assess financial impact on Partners’ hospitals. He also tracked the rule-making process for federal/state payment systems and drafted feedback to CMS on reimbursement and quality proposals. Prior to this, he was a research assistant at the Dana-Farber Cancer Institute in the Department of Cell Therapies, working with bone marrow transplant patients and collaborating on patient education efforts. He has also worked on health policy and communications for the American College of Physicians.

Kolton has an MPH in health policy from the Harvard T. H. Chan School of Public Health and a BA in political science from the George Washington University.

Authored Content


Policy changes to Medicare’s CAR-T inpatient reimbursement set a precedent for high-cost durable treatments. Looking ahead, questions and concerns remain for pipeline cell and gene therapies that have high up-front costs.

As our healthcare industry rapidly evolves to address the COVID-19 pandemic, keep track of new resources and policies affecting patients and providers with the COVID-19 guide below.

Avalere assessed the impacts of select policies to expand low-income subsidy (LIS) eligibility under Medicare Part D